EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
Aleksandar Milovancev,1 Vladimir Stojsic,1 Bojan Zaric,1 Tomi Kovacevic,1 Tatjana Sarcev,1 Branislav Perin,1 Konstantinos Zarogoulidis,2 Katerina Tsirgogianni,2 Lutz Freitag,3 Kaid Darwiche,3 Drosos Tsavlis,2 Athanasios Zissimopoulos,4 Grigoris Stratakos,5 Paul Zarogoulidis2 1Institute for Pulmonar...
Main Authors: | Milovancev A, Stojsic V, Zaric B, Kovacevic T, Sarcev T, Perin B, Zarogoulidis K, Tsirgogianni K, Freitag L, Darwiche K, Tsavlis D, Zissimopoulos A, Stratakos G, Zarogoulidis P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-10-01
|
Series: | OncoTargets and Therapy |
Online Access: | https://www.dovepress.com/egfr-tkis-in-adjuvant-treatment-of-lung-cancer-to-give-or-not-to-give-peer-reviewed-article-OTT |
Similar Items
-
Personalized Approach to Tissue and Liquid Biopsy after Failure of First-Line EGFR-TKIs: Is There an Issue When Tissue Is Not the Issue? A Case Series
by: Daliborka Bursac, et al.
Published: (2021-05-01) -
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01) -
The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
by: Chutong Lin, et al.
Published: (2021-04-01) -
Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung Adenocarcinoma
by: Qiwen Li, et al.
Published: (2021-04-01) -
EGFR-TKIs resistance via EGFR-independent signaling pathways
by: Qian Liu, et al.
Published: (2018-02-01)